DERMATOP ® Prednicarbato

DERMATOP ® is a drug based on Prednicarbato

THERAPEUTIC GROUP: Non-associated corticosteroids, dermatological preparations

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions DERMATOP ® Prednicarbato

DERMATOP ® is indicated for the treatment of inflammatory skin conditions such as dermatosis, dermatitis, eczema and psoriasis sensitive to corticosteroid therapy.

Mechanism of action DERMATOP ® Prednicarbato

The Prednicarbato, active principle of DERMATOP ®, is a non-halogenated synthetic corticosteroid, characterized by a therapeutic efficacy comparable to that of the most powerful cortisones but with a decidedly better safety profile.

In fact, the many experimental studies carried out have demonstrated the low toxicity of the aforementioned active principle, highlighting first of all the low systemic absorption of the drug following topical application and also the effective hepatic metabolism to which the possibly absorbed quota is subjected.

Its therapeutic efficacy on the other hand is due to the typical ability of corticosteroids to induce the expression of proteins such as Lipocortin, capable of inhibiting the activity of enzymes involved in the cascade of events that leads to the production of inflammatory cytokines and in particular prostaglandins .

The reduced production of these mediators, also associated with a potential anti-chemotactic activity against mast cells and other inflammatory cells, ensures optimal control of inflammatory events and associated symptoms.

Studies carried out and clinical efficacy

PREDNICARBATO AND ACNEIFORM EXAMINATION

Eur J Dermatol. 2010 Jan-Feb; 20 (1): 82-4. doi: 10.1684 / ejd.2010.0806. Epub 2009 Oct 2.

Clinical study that demonstrates the effectiveness of the Prednicarbate associated with an antibiotic in significantly improving the acneiform skin lesions present in a patient treated with cetuximab.

PREDNICARBATED PHARMACOCINETICS

Eur J Pharm Biopharm. 2013 Jun; 84 (2): 374-85. doi: 10.1016 / j.ejpb.2012.11.008. Epub 2012 Nov 29.

Experimental study that tries to best characterize the biotransformation that Prednicarbate faces following a topical application. This evidence could be important in better managing all potential therapies.

THE PREDNICARBATED IN THE TREATMENT OF DERMATOLOGICAL DISEASES

BioDrugs. 1998 Jan; 9 (1): 61-86.

Very interesting review that re-evaluates the effectiveness of the treatment with Prednicarbato in a series of dermatological pathologies, demonstrating its excellent efficacy and equally good safety of use, without highlighting clinically relevant adverse reactions.

Method of use and dosage

DERMATOP ®

Dermatological cream, ointment, lipophilic cream and 0.25% cutaneous solution of Prednicarbato.

Generally it is recommended to apply the appropriate quantity of medicine, directly on the region affected by the damaging process, once or twice a day, taking care to lightly rub the same area in order to guarantee the absorption of the medicine.

The definition of the dosing schedule, the choice of the format and the duration of the therapy must necessarily be defined by your doctor based on the severity of the present clinical picture.

Warnings DERMATOP ® Prednicarbato

The initial medical examination is a mandatory and fundamental step in DERMATOP ® therapy, in order to minimize the potential side effects while enhancing the therapeutic ones.

For this reason the doctor should inform the patient about the correct application of the medicine, underlining the need to avoid prolonged or interval treatments, the need to avoid contact of the drug with eyes, mucous membranes or severely damaged areas, the need to lend attention to the possible occurrence of adverse reactions.

It is also useful to inform the patient about the potential side effects of corticosteroid therapy, even if topically set.

PREGNANCY AND BREASTFEEDING

The absence of clinical trials able to better characterize the safety profile of DERMATOP ® for the health of the fetus and the infant, extend the aforementioned contraindications to the use of the drug also to pregnancy and the subsequent period of breastfeeding.

Use in these circumstances could only be justified by cases of real necessity and only take place under the strict supervision of your doctor.

Interactions

No known drug interactions are currently known.

Contraindications DERMATOP ® Prednicarbato

The use of DERMATOP ® is contraindicated in patients hypersensitive to the active ingredient or to one of its excipients, in patients suffering from fungal, viral or bacterial infections (not adequately treated), in patients with perioral lesions and during pregnancy and lactation .

Undesirable effects - Side effects

The use of topical corticosteroids, especially when prolonged over time, could lead to the appearance of local adverse reactions such as: edema, burning, irritation, hair loss, hypertrichosis, skin atrophy, skin dryness and dermatitis.

Systemic side effects are far rarer.